High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
Intensive doses of carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support were given to four patients with advanced melanoma. Three developed clinically diagnosed, severe veno-occlusive liver disease, which was fatal in two cases. The dose of carboplatin (450 mg/m2) was comparable with that used in ambulatory regimens. At the doses and schedule employed, this three-drug combination produced excessive hepatic toxicity. Caution is suggested when giving carboplatin in combination with intensive doses of other chemotherapeutic agents with known hepatotoxic potential.
Jones
R B
RB
Bone Marrow Transplantation Program, Duke University Comprehensive Cancer Center, Durham, NC 27710.
Shpall
E J
EJ
Ross
M
M
Coniglio
D
D
Affronti
M L
ML
Peters
W P
WP
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D016026:Bone Marrow Transplantation; D016190:Carboplatin; D002330:Carmustine / Q000008:administration & dosage / Q000633:toxicity; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000633:toxicity
D009944:Organoplatinum Compounds; D003520:Cyclophosphamide; D016190:Carboplatin; D002330:Carmustine